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Abstract The aim of this study was to investigate the
mechanism and site of action of betahistine dihydrochlo-
ride in the inner ear of the guinea pig. Betahistine-evoked
increases in cochlear blood flow (CBF) have been pre-
sumed to be due to the drug effect on the later wall capil-
lary bed or larger feeding vessels in the cochlea vascular
system. As such, the mechanism of action could be due to
inhibition of H3 receptors. Betahistine may also have a di-
rect effect on postsynaptic H1/H2 receptors and/or an ef-
fect modulated by other autonomic receptors. Betahistine-
evoked CBF responses were assessed by laser Doppler
flowmetry in the presence of an H3 agonist (αN-methyl-
histamine dihydrochloride), an H3 antagonist (thiopera-
mide), an H2 antagonist (cimetidine) or an α2 antagonist
(idazoxan). The effects of betahistine on circulation in the
anterior inferior cerebellar artery (AICA) and ipsilateral
stria vascularis (SV) were assessed using intravital mi-
croscopy (IVM). Findings showed that betahistine in-
creased CBF and reduced systemic blood pressure (BP).
In contrast, αN-methylhistamine dihydrochloride had no
effect on baseline CBF or BP and did not influence be-
tahistine-induced increases in CBF. Thioperamide re-
versed the effects of betahistine on CBF, but had no effect
on baseline CBF or BP. Cimetidine had no marked effect
on baseline CBF or betahistine-induced increases in CBF
Idazoxan had no consistent effects on baseline CBF, but
abolished the effect of betahistine on CBF. The mean in-
crease of red blood cell velocity in SV capillaries was
15% and occurred without a demonstrable change in cap-
illary diameters. In contrast, the diameter of the AICA in-
creased by 17–20%, indicating that betahistine-evoked in-
creases in CBF resulted primarily from vasodilatation of
the AICA. We suggest that this effect may be mediated
via presynaptic H3 heteroreceptors and autonomic α2 re-
ceptors.
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Introduction
Betahistine dihydrochloride is considered to be one of the
few vasoactive drugs that may have clinically beneficial
effects on such inner ear disorders as Menière’s disease
and tinnitus [7]. Although vasodilatation due to direct
stimulation of histaminergic H1 and H2 receptors has been
suggested to be a contributing factor to these effects, be-
tahistine is recognized to have only a weak effect on these
receptors [8]. This study was carried out to further inves-
tigate the possible mechanism and site of action of be-
tahistine on cochlear blood flow (CBF).
In a recent study, administration of betahistine either
intravenously, or topically to the round window membrane,
or via the anterior inferior cerebellar artery (AICA) result-
ed in a specific effect on cochlear vessels [4]. This response
was not affected by promethazine as an H1 histaminergic
antagonist. In separate studies Arrang et al. [1] have de-
scribed a novel H3 inhibitory presynaptic receptor. Action
at this presynaptic receptor may have two effects: stimu-
lation may cause an inhibition of histamine release to the
postsynaptic site, or it may interact with other autonomic
receptors to co-modulate vessel tone. Elsewhere, Ischi-
kawa and Sperilakis [3] have reported an interaction be-
tween H3 and adrenergic receptors in the peripheral ner-
vous system.
As betahistine is recognized to be a strong H3 receptor
antagonist [2], it is possible that betahistine-evoked in-
creases in CBF could be due to inhibition of H3 receptors,
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thus causing an increase in histamine release and activa-
tion of postsynaptic H1 and H2 receptors. In addition, be-
tahistine may have a weak, but direct, effect on postsy-
naptic H1 and H2 receptors and/or an effect modulated by
other autonomic receptors. Indeed, in noradrenergic and
cholinergic systems, the inhibitory presynaptic α2 recep-
tor has been shown to mediate electrically stimulated in-
creases in CBF [5]. However, it is possible that more than
one of these mechanisms of action may contribute to the
clinical benefits of betahistine.
In our current study, potential mechanisms of betahis-
tine as cochlear blood flow were assessed by determining
the effects of a specific H3 antagonist, an H3 agonist, an
H2 antagonist and an α2 antagonist on betahistine-evoked
increases in CBF, using the guinea pig as an animal
model. The site of action was also assessed by observing
the vascular responses to betahistine in different regions
of the cochlear vascular system, i.e., as the AICA and ip-
silateral stria vascularis (SV).
Materials and methods
Animals and preparation
Eighteen healthy adult male and female pigmented guinea pigs
(weighing 310–400 g) were used to assess the mechanism of action
of betahistine. The study was consistent with the United States Na-
tional Institute of Health (NIH) guidelines for the humane treat-
ment of animals. The middle ear was examined in each animal
prior to study in order to exclude ears with incidental infections.
Animals were anesthetized with intraperitoneal pentobarbital
(Nembutal) as 25 mg/ml or 0.6 ml/kg and in transmuscular fen-
tanyl with properidol (Innovar) as 0.4 mg/kg. Anestetics were pro-
vided by Sigma Chemicals (St. Louis, Mo., USA). An additional
half dose of Innovar was administered every 30 min in order to
maintain anesthesia.
Following tracheotomy, the carotid artery was cannulated for
systemic blood pressure (BP) measurements while both external
jugular veins were used for drug administration. The head was
then fixed in a head restraint, and each animal being studied was
wrapped in a heating pad with a feedback system in order to main-
tain core temperature at 38 ± 1°C.
For laser Doppler flowmetry, TSI (TSI, Minnesota, USA) and
Perimed PF3 (Perimed, Sweden) laser flowmeters were used as de-
scribed in detail by Miller and Nuttall [6]. The tympanic bullae
were exposed surgically using a ventral approach, the mucosa over
the second turn of the cochlea was gently removed and petroleum
jelly was applied between the laser probe and the bone in order to
improve optical coupling. Measurements were made over the sec-
ond turn by placing the probe perpendicular to the stria. CBF, BP
and the conductivity of the cochlear vascular system (R CBF/BP)
were recorded on a strip chart recorder. R was used to express CBF
independent of any changes in local perfusion pressure. Final re-
sults were described in terms of the change (%∆CBF and %∆BP)
from mean baseline levels, with baseline levels determined over a
period of at least 15 min before each experiment.
The effects of betahistine on circulation in the AICA and SV
were also observed in two guinea pigs using intravital microscopy
(IVM). Each animal’s brainstem was exposed by removing the
esophagus and deeper straight neck muscles, after which the bony
skull base was drilled off. Following penetration of the aura, the
AICA was characteristically found to branch from the basilar
artery. For IVM observations of CBF, small windows were created
with a 1-mm diamond drill in two or three sites over the membra-
nous labyrinth. Systemically administered fluorescein was used to
enhance the contrast of microcirculation in the lateral wall capil-
laries.
Experimental procedures
To verify a betahistine effect on CBF or study the interactions with
other agents (see below), 12.4 mM betahistine was administered
systemically via a Sage 350 infusion pump into the left external
jugular vein of six animals for 2 min at a rate of 0.3 ml/min. All
other drugs were infused into the right external jugular vein using
a Sage model 354 infusion pump.
Mode of action of betahistine
αN-Methylhistamine dihydrochloride (RBI, Natick, Mass., USA)
at a concentration of 12.5 mM was infused at a rate of 0.3 1 ml/min
for 2 min and was administered 10 min before any betahistine in-
fusion in order to assess the effect of a specific H3 receptor agonist
on CBF and the effect of chemical stimulation of H3 receptors on
betahistine-evoked increases in CBF in four animals. This proce-
dure was repeated twice in each animal following a 30-min recov-
ery period between infusions.
The same procedures were used to assess the effects of 6, 9, 12
and 16 mM thioperamiede as a specific H3 receptor antagonist.
Drug was obtained from RBI and was infused for 2 min at a rate of
0.3 ml/min. Cimetidine (Sigma Chemicals) was used as a specific
H2 antagonist and was infused in concentrations of 8, 16, 24 and
32 mM at a rate of 0.3 ml/min for 2 min in five animals. Idazoxan
(Sigma Chemicals) served as α2-antagonist at concentrations of 3,
6, 9 and 12 mM and was infused at a rate of 0.3 ml/min for 2 min
in five animals. Although a 30-min recovery period was main-
tained between infusions, the result of each infusion represented a
cumulative effect of the drug employed.
Site of action of betahistine
Observations of circulation in the AICA and SV during betahistine
infusions were made using IVM via small windows over the basal,
second and third turns of the cochlea. The effect of betahistine on
AICA and SV diameter was also assessed under a surgical micro-
scope at × 450 (AICA) or × 1000 (SV) magnification (Fig. 3).
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Table 1 Effects of αN-methyl-
histamine dihydrochloride as
H3 antagonist, thioperamide as
H3 antagonist, cimetidine as H2
antagonist and idazoxan as α2
antagonist on baseline cochlear
blood flow (CBF) and betahis-
tine-evoked increases in CBF
Receptor Mode of Effect on Effect on
action baseline betahistine-evoked
increases in CBF
αN-Methylhistamine Histaminergic H3 Agonist None None
dihydrochloride
Cimetidine Histaminergic H2 Antagonist None None
Idazoxan α2 Antagonist None Inhibtion
Thioperamide Histaminergic H3 Antagonist None Inhibition
Results
Each infusion of betahistine resulted in a mean increase of
40% in CBF and a mean decrease of 10% in systemic BP
compared with baseline (Fig. 1). Due to systemic effects,
the conductivity of the vascular bed in the cochlea in-
creased by up to 50% above baseline. CBF returned to
baseline levels within 3–4 min of the infusion being ter-
minated.
Mode of action of betahistine
As shown in Table 1, betahistine infusions resulted as an
increased CBF. In contrast, αN-methylhistamine dihy-
drochloride had no significant effect on baseline CBF or
BP and did not influence betahistine-induced increases in
CBF. However, thioperamide completely reversed the ef-
fects of betahistine on CBF. This latter effect showed lit-
tle dose-dependence and was almost maximal at the low-
est dose used (6 mM). As seen with αN-methylhistamine
dihydrochloride, thioperamide had no effect on baseline
CBF or BP. Increasing doses of both αN-methylhistamine
dihydrochloride and thioperamide caused convulsions,
followed by sudden cardiac arrest and immediate death,
but without any specific changes in CBF.
Cimetidine had no marked effect on CBF, although
high doses (up to 30 mM) resulted in a reduction in BP
and a subsequent reduction in CBF. Cimetidine had no
significant effect on betahistine-induced increases in
CBF.
Idazoxan reduced baseline CBF in some animals by
5–10%, but this reduction was not consistent throughout
the study, and therefore its significance remains unclear.
Further assessment in relation to the tonic level of auto-
nomic activity is required. However, idazoxan abolished
the effect of betahistine on CBF; this response showed
some dose-dependency (Fig. 2).
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Fig. 1 The effect of betahistine
infusion on cochlear blood
flow (CBF), blood pressure
(BP) and cochlear vascular
conductivity (CBF/BP). 
Values shown are mean ±
SEM (n = 5)
Fig. 2 The effect of idazoxan
infusion on betahistine-evoked
increases in CBF. Results pre-
sented are from one representa-
tive experiment
Site of action of betahistine
CBF during betahistine infusion was observed in a total of
30 vessels. The mean increase of red blood cell velocity in
SV capillaries was 15% and occurred without a change in
capillary diameter. The diameter of AICA increased by
17–20% (from 93–101 µm to 105–121 µm).
Discussion
It has previously been shown that H1-receptor antagonists
do not significantly affect betahistine-evoked changes in
CBF [4]. The findings in our current study indicate that
drugs acting at the H2 receptor also have no effect on the
response to betahistine, while another H3 antagonist, thi-
operamide, inhibits the effects of betahistine. This sug-
gests that betahistine-evoked increases in CBF are due to
a specific effect on presynaptic H3 receptors in the co-
chlear vascular system. As the effect of betahistine is in-
fluenced by actions at presynaptic α2 receptors, the H3 re-
ceptors involved in the action of betahistine may be “het-
eroreceptors” that interact with both histaminergic and au-
tonomic receptors in the periphery [3]. The finding that
the specific H3 receptor antagonist, thioperamide, and the
H3 agonist, αN-methylhistamine dihydrochloride, had no
effect on baseline CBF indicates that these drugs can oc-
cupy H3 receptors (and so inhibit the action of betahis-
tine), but they cannot interact with the vasoactive systems
in the periphery necessary to affect CBF.
As it is difficult to measure modest changes in capil-
lary diameter accurately using IVM and fluorescein, po-
tential small changes associated with betahistine cannot
be excluded. However, as betahistine receptors are
thought most likely to be located on smooth muscle or on
nerve innervating smooth muscle (neither of which are
present in the lateral wall capillaries of the cochlea), such
an effect is unlikely. The effects of betahistine on AICA
and SV in our current study support these findings. This
finding is also consistent with our earlier observations in
which betahistine applied locally to the round window
membrane produced a clear effect on cochlear electro-
physiology but no change in CBF [4].
The cochlea has a strong autoregulatory capacity that
compensates easily for small changes in cochlear circula-
tion, such as those seen in AICA diameter in our current
study. The marked increase in red blood cell velocity in
the stria capillaries is therefore indicative of similar, more
general smooth muscle responses in the inner ear vascular
system (e.g., in the labyrinthine, spiral modiolar and radi-
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Fig.3 a–c The effect of betahistine infusion on AICA diameter in
one representative experiment. a Control infusion: vessel diameter
90 µm; b effect during drug infusion: vessel diameter 115 µm; c 10
min after drug infusion: vessel diameter 98 µm. Original magnifi-
cation for AICA × 450, for SV × 1000
a b
c
ating arterioles of the cochlea). Thus, betahistine is likely
also to have an effect on the vestibular circulation.
The dose of betahistine used in our current study was
selected to produce an effect that was clear, but well
within a physiological range. The animals tolerated such
treatment well and their respiratory and cardiovascular
functions were only slightly affected by the infusion. The
vascular actions of betahistine appear directly to affect not
only the membranous vasculature in the cochlea, but also
the larger afferent vessels derived from AICA. Thus, be-
tahistine may affect the vestibular organ circulation as
well as the cochlear circulation. This is an important ob-
servation in the search for the basic mechanism of action
of betahistine in the treatment of vestibulo-cochlear disor-
ders, although it must be realized that the dose infused in
our current study was three to four times the usual oral
dose employed in the clinical management of patients.
This suggests that the effects of betahistine on CBF in pa-
tients are relatively small and may not be the only mecha-
nism of action by which this drug exerts a beneficial ef-
fect on vestibulo-cochlear disorders.
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